Discover effective strategies for monitoring and managing CRS toxicity and ICANS, enhancing patient care and reducing burdens ...
Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...
SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or refractory follicular lymphoma.
Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...
Follicular lymphoma is framed as highly treatable yet chronic and incurable, with remission achieved after six months despite extensive baseline disease burden. Maintenance immunotherapy administered ...
With a new FDA nod, BeiGene has filled the follicular lymphoma approval gap for BTK inhibitors. Thursday, the FDA doled out an accelerated approval for BeiGene’s Brukinsa to be used alongside Roche’s ...
Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses the growing view that follicular lymphoma could be viewed as ...
Sponsored advertising content is provided by Genmab A/S and AbbVie and does not necessarily reflect the views of CURE Each person’s experience with follicular lymphoma (FL) is unique. Whether you’re ...
-- Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGene -- IFLI contributed up to $9 million to Enterome's private funding round in 2025 -- Enterome has announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results